MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2011.12.011

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2012

Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.

Maibach Rudolf, Roebuck Derek, Brugieres Laurence, Capra Michael, Brock Penelope, Dall'Igna Patrizia, Otte Jean-Bernard, De Camargo Beatriz, Zsiros Jozsef, Zimmermann Arthur, Aronson Daniel, Childs Margaret, Scopinaro Marcelo, Morland Bruce, Plaschkes Jack, Czauderna Piotr, Perilongo Giorgio

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: To identify factors relevant to long-term outcome in newly diagnosed hepatoblastoma, and define subgroups for clinical research on tailoring treatment to the individual patient.

PATIENTS AND

METHODS

Between 1995 and 2006 the SIOPEL group conducted two clinical trials which established risk-adapted therapy for hepatoblastoma patients. Patients were stratified into high-risk (AFP < 100 ng/mL and/or PRETEXT IV and/or vascular invasion and/or extra-hepatic intra-abdominal disease (V+/P+/E+) and/or metastases) and standard-risk (all others). The hierarchy of these factors plus multifocality, PRETEXT III, AFP > 1,200,000 ng/mL, patient age, platelet count and histology were further explored. The outcome measure was event-free survival (EFS).

RESULTS

In 541 patients, reduced EFS correlated significantly with AFP < 100 ng/ml (hazard ratio [HR] 4.09, 95% confidence interval 2.16-7.75), AFP ≥ 1.2 × 10(6)ng/mL (2.48, 1.47-4.17), metastatic disease (3.02, 2.05-4.44), PRETEXT IV (2.15, 1.19-3.87), multifocality (1.59, 1.01-2.50), age > 5 years (2.76, 1.68-4.53); borderline with small cell undifferentiated (SCU) histology (2.29, 95% confidence interval 0.91-5.77); but not with PRETEXT III, age 30-60 months, platelet count or V+/P+/E+. By using the significant factors and SCU to stratify the population, we have identified three distinct prognostic groups: PRETEXT I/II/III, and no other factors, have 3 year EFS of 90%, PRETEXT IV and/or multifocal tumour and/or age> 5 years and/or AFP > 1.2 × 10(6) have 3 year EFS of 71% and SCU and/or AFP < 100 ng/mL and/or metastatic have a 3year EFS of 49%.

CONCLUSION

Prognostic stratification for clinical research on newly diagnosed hepatoblastoma should take into consideration PRETEXT, metastatic disease, AFP, multifocality, age and SCU histology.

Для цитирования: Maibach Rudolf, Roebuck Derek, Brugieres Laurence, Capra Michael, Brock Penelope, Dall'Igna Patrizia, Otte Jean-Bernard, De Camargo Beatriz, Zsiros Jozsef, Zimmermann Arthur, Aronson Daniel, Childs Margaret, Scopinaro Marcelo, Morland Bruce, Plaschkes Jack, Czauderna Piotr, Perilongo Giorgio. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.. European journal of cancer (Oxford, England : 1990). 2012. DOI: 10.1016/j.ejca.2011.12.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.